Want to see PURE full AI Analyst Report?
Pure Bioscience (PURE) Risk Analysis
Risk Overview Q1, 2026
Source: the company's latest filing for the period ended Apr 30, 2026, filed Jun 15, 2026
Risk Change Over Time
- Debt & Financing - Risk 1As a result of our historical lack of financial liquidity, we do not currently have sufficient working capital to fund our planned operations and may not be able to continue as a going concern.
We have a history of recurring losses, and as of April 30, 2026 we have a stockholder deficiency of $5,839,000. During the nine months ended April 30, 2026, we recorded a net loss of $1,873,000 on recorded net revenue of $1,658,000. In addition, during the nine months ended April 30, 2026, we used $1,324,000 in operating activities resulting in a cash balance of $983,000 as of April 30, 2026. As a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve months from the date hereof, and we will need to raise additional capital to continue our operations and to implement our business plan, which capital may not be available on acceptable terms or at all. Our capital requirements will depend on many factors, including, among others: - the market acceptance of, and demand for, our products; - the timing and costs of executing our sales and marketing strategies; - our ability to successfully complete the in-plant validation trials requested by potential customers and our ability to convert these trials into customer orders for our products; - the costs and time required to obtain the necessary regulatory approvals for our products, including the required USDA approvals: - the extent to which we invest in new testing and product development, including in-plant optimization trials; - the extent to which our customers continue to place product orders as expected and expand their existing use of our products; - the cost and time to satisfy unique customer requirements regarding validation trials or to support the value proposition and benefits of our products; - the timing of vendor payments and the collection of receivables, among other factors affecting our working capital; - our ability to control the timing and amount of our operating expenses, including the costs to attract and retain personnel with the skills required to implement our business plan; and - the costs to file, prosecute and defend our intellectual property rights. The above factors, along with our history and near term forecast of incurring net losses and negative operating cash flows, raise substantial doubt about our ability to continue as a going concern. If we do not obtain additional capital from external sources, we will not have sufficient working capital to fund our planned operations or be able to continue as a going concern. We cannot assure you that additional financing will be available when needed or that, if available, we can obtain financing on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.
Risk Highlights Q1, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 39
- Share Price & Shareholder Rights - Risk 1Our common stock is deemed to be "penny stock," which may make it more difficult for investors to sell their shares due to suitability requirements.
Shares of our common stock are subject to the so-called "penny stock" rules as that term is defined in Rule 3a51-1 promulgated under the Securities Exchange Act of 1934. These requirements may reduce the potential market for our common stock by reducing the number of potential investors. This may make it more difficult for investors in our common stock to sell shares to third parties or to otherwise dispose of them. This could cause our stock price to decline. Broker-dealers dealing in penny stocks are required to provide potential investors with a document disclosing the risks of penny stock. Moreover, broker-dealers are required to determine whether an investment in a penny stock is a suitable investment for a prospective investor. Such requirements may discourage broker-dealers from effecting transactions in our common stock, which could limit the market price and liquidity of our common stock.
- Share Price & Shareholder Rights - Risk 2Potential sales or issuances of our common stock to raise capital, or the perception that such sales could occur, could cause dilution to our current stockholders and the price of our common stock to fall.
We have historically supported our operations through the issuance of equity and debt securities and may continue to do so in the future. For example, during the fiscal year ended July 31, 2025 and 2024, we completed a private placement convertible debt financing to accredited investors, in which we raised net proceeds of $3.8 million. Pursuant to the terms of the Purchase Agreement, the conversion price for the convertible debt financing will be at least $0.115 per share and less than or equal to $0.23 per share. Although we may not be successful in obtaining financing through equity or debt sales on terms that are favorable to us in the future, if at all, any such sales that do occur could result in substantial dilution to the interests of existing holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock or other equity securities to any new investors, or the anticipation of such sales, could cause the trading price of our common stock to fall.
- Share Price & Shareholder Rights - Risk 3The price of our common stock has been and may continue to be volatile.
Our common stock is approved for quotation on the over-the-counter, or OTC Markets' OTCQB marketplace, or OTCQB under the symbol "PURE." The OTCQB is a regulated quotation service that displays real-time quotes, last-sale prices and volume information in over-the-counter equity securities and provides significantly less liquidity than a listing on the Nasdaq Stock Markets or other national securities exchange. The OTCQB securities are traded by a community of market makers that enter quotes and trade reports. This market is limited in comparison to the national stock exchanges and any prices quoted may not be a reliable indication of the value of our common stock. Quotes for stocks included on the OTCQB are not listed in the financial sections of newspapers as are those for the Nasdaq Stock Market or the New York Stock Exchange, or NYSE MKT. Therefore, prices for securities traded solely on the OTCQB may be difficult to obtain. Trading on the OTCQB as opposed to a national securities exchange has resulted and may continue to result in a reduction in some or all of the following, each of which could have a material adverse effect on the price of our common stock and our company: - the liquidity of our common stock; - the market price of shares of our common stock; - our ability to obtain financing to support our operations and the implementation of our business plan; - the number of institutional and other investors that will consider investing in shares of our common stock; - the number of market markers in shares of our common stock; - the availability of information concerning the trading prices and volume of shares of our common stock; and - the number of broker-dealers willing to execute trades in shares of our common stock. The price and trading volume of our common stock have historically been volatile. In addition, the market price and trading volume of our common stock may be subject to wide fluctuations in the future in response to: - actual or anticipated fluctuations in our results of operations; - announcements regarding the status of our regulatory efforts; - the determination that our shares of common stock are "penny stock" which will require brokers trading in our shares of common stock to adhere to more stringent rules, likely resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock; - the sale by us of our common or preferred stock or other securities, or the anticipation of sales of such securities; - the trading volume of our common stock, particularly if such volume is light; - the introduction of new products or services, or product or service enhancements by us or our competitors; - developments with respect to our or our competitors' intellectual property rights or regulatory approvals or denials; - announcements of significant acquisitions or other agreements by us or our competitors; - sales or anticipated sales of our common stock by our insiders (management and directors); - conditions and trends in our industry; - changes in our pricing policies or the pricing policies of our competitors; - changes in the estimation of the future size and growth of our markets; and - general economic conditions. In addition, the stock market in general, the OTCQB, and the market for shares of novel technology companies in particular, have experienced extreme price and volume fluctuations that in some cases may be unrelated or disproportionate to the operating performance of those companies. These broad market and industry factors may materially harm the market price of our common stock, regardless of our operating performance. In addition, this volatility could adversely affect an investor's ability to sell shares of our common stock, and/or the available price for such shares, at any given time.
- Share Price & Shareholder Rights - Risk 4Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control and could also limit the market price of our stock.
Certain provisions of our charter and bylaws, as amended, or Bylaws, may delay or frustrate the removal of incumbent directors and may prevent or delay a merger, tender offer, or proxy contest involving us that is not approved by our Board, even if such events may be beneficial to the interests of stockholders. For example, our Board, without stockholder approval, has the authority and power to authorize the issuance of up to 5,000,000 shares of preferred stock and such preferred stock could have voting or conversion rights that could adversely affect the voting power of the holders of our common stock. Further, the one-for-eight reverse stock split of our outstanding common stock that we effected on August 14, 2012 has increased the proportion of unissued and authorized common shares to issued and outstanding common shares, which could allow our Board to issue large numbers of additional shares of our common stock that could significantly reduce the voting power of our current stockholders. In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our charter documents may make it more difficult for stockholders or potential acquirers to initiate actions that are opposed by our then-current Board, including delaying or impeding a merger, tender offer, or proxy contest or other change of control transaction involving the Company. Any delay or prevention of a change of control transaction could cause stockholders to lose a substantial premium over the then-current market price of their shares.
- Share Price & Shareholder Rights - Risk 5Raising additional funds by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders, restrict our operations or require us to relinquish proprietary rights.
We may need to increase our liquidity and capital resources in future periods. We have a history of raising funds through offerings of our common stock and warrants to purchase shares of our common stock, and we may in the future raise additional funds through public or private equity offerings, debt financings or corporate collaborations and licensing arrangements. For example, during fiscal year ended July 31, 2025, we completed a private placement convertible debt financing to accredited investors, in which we raised net proceeds of $2.0 million. To the extent that we continue to raise additional capital by issuing debt or equity securities, our stockholders' ownership will be diluted. Additionally, any debt financing we obtain may involve covenants that restrict our operations. These restrictive covenants may include, among other things, limitations on borrowing, specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens on our assets, pay dividends on or redeem our capital stock or make investments. In addition, if we raise funds through collaboration and licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to us or relinquish potentially valuable rights to our products or proprietary technologies. We may be required in future collaborations to relinquish all or a portion of our sales and marketing rights with respect to our products or license intellectual property that enable licensees to develop competing products in order to complete any such transaction. As of October 29, 2025, we had 164,984,696 shares of common stock issued and outstanding or reserved for issuance under equity compensation plans, vested and unvested options, unvested restricted stock units and convertible debt. Our current authorized capital stock is limited to 200,000,000 shares of common stock and 5,000,000 shares of preferred stock. Any increase in our authorized capital stock would require the approval of a majority of our shareholders as well as the approval of our Board of Directors, or Board. If we were unable to increase our authorized capital stock for any reason, our ability to raise additional capital through the issuance of equity or convertible debt would be severely compromised and we may be unable to obtain equity or convertible debt capital at all.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.
